We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

66 hedge funds and large institutions have $272M invested in TScan Therapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

45% more capital invested

Capital invested by funds: $187M → $272M (+$84.9M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

22% more funds holding

Funds holding: 54 → 66 (+12)

4.82% more ownership

Funds ownership: 73.82% → 78.64% (+4.8%)

Holders
66
Holders Change
+12
Holders Change %
+22.22%
% of All Funds
0.95%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
17
Increased
22
Reduced
9
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$3.07M
2
LCM
Laurion Capital Management
New York
+$1.9M
3
Millennium Management
Millennium Management
New York
+$1.84M
4
Goldman Sachs
Goldman Sachs
New York
+$1.45M
5
TAM
Tocqueville Asset Management
New York
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.54M
2
6CM
683 Capital Management
New York
-$252K
3
ECM
ExodusPoint Capital Management
New York
-$177K
4
BCM
Bridgeway Capital Management
Texas
-$157K
5
Stifel Financial
Stifel Financial
Missouri
-$120K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$928K +$275K +43,758 +60%
Stifel Financial
27
Stifel Financial
Missouri
$805K -$120K -19,000 -16%
NW
28
NewEdge Wealth
Pennsylvania
$791K – – –
Man Group
29
Man Group
United Kingdom
$614K +$169K +26,929 +53%
Northern Trust
30
Northern Trust
Illinois
$611K +$33.6K +5,349 +7%
JP Morgan Chase
31
JP Morgan Chase
New York
$532K +$213K +33,783 +102%
BCM
32
Bridgeway Capital Management
Texas
$503K -$157K -25,000 -28%
Walleye Capital
33
Walleye Capital
New York
$417K +$218K +34,701 +195%
MTIM
34
Marathon Trading Investment Management
Pennsylvania
$405K +$321K +51,000 New
Renaissance Technologies
35
Renaissance Technologies
New York
$373K +$159K +25,300 +117%
CSS
36
Cubist Systematic Strategies
Connecticut
$352K +$114K +18,063 +69%
Balyasny Asset Management
37
Balyasny Asset Management
Illinois
$333K -$25.4K -4,044 -9%
Two Sigma Investments
38
Two Sigma Investments
New York
$300K +$237K +37,747 New
ECM
39
ExodusPoint Capital Management
New York
$283K -$177K -28,117 -44%
DIM
40
DC Investments Management
Virginia
$282K – – –
HF
41
HRT Financial
New York
$276K +$219K +34,789 New
BHCM
42
Brevan Howard Capital Management
Jersey
$275K +$218K +34,578 New
American Century Companies
43
American Century Companies
Missouri
$253K +$66.5K +10,570 +50%
Bank of America
44
Bank of America
North Carolina
$240K -$48K -7,625 -20%
YIH
45
Y-Intercept (HK)
Hong Kong
$194K +$59.4K +9,441 +63%
Charles Schwab
46
Charles Schwab
California
$176K – – –
PFCS
47
Pale Fire Capital SE
Czech Republic
$171K – – –
LBA
48
Letko, Brosseau & Associates
Quebec, Canada
$164K – – –
PAS
49
Point72 Asia (Singapore)
Singapore
$157K +$124K +19,736 New
CGIM
50
Cannon Global Investment Management
Florida
$139K +$110K +17,500 New
1
2
3

TCRX Hedge Fund Activity: Q1 2024 in Review

66 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2024, worth a combined $272M — up 45% from $187M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new TCRX positions and 5 closed out — a net gain of 12 holders — while 22 added to existing stakes and 9 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $3.07M. The largest seller was Morgan Stanley, cutting an estimated $1.54M.

  • 66 institutional investors held TScan Therapeutics (TCRX) as of Q1 2024, up from 54 in Q4 2023.
  • Funds reported $272M of TScan Therapeutics stock for Q1 2024, up 45% quarter-over-quarter.
  • 17 funds opened new TScan Therapeutics positions in Q1 2024 and 5 closed out, a net change of +12 holders.
  • The largest TScan Therapeutics buyer in Q1 2024 was Invesco, an estimated $3.07M added.
  • The largest TScan Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $1.54M sold.

Based on aggregated 13F filings for Q1 2024.